within Pharmacolibrary.Drugs.ATC.N;

model N02AF02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 1.2833333333333334,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.2,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Nalbuphine is a synthetic opioid analgesic used to treat moderate to severe pain. It acts as a mixed agonist-antagonist at opioid receptors—agonist at kappa-opioid receptors and antagonist at mu-opioid receptors. It is primarily approved for use in the management and relief of pain, pre- and postoperative analgesia, and as a supplement to balanced anesthesia. It is currently approved for medical use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Pfiffner, M, et al., &amp; Berger-Olah, E (2023). Pharmacokinetics and tolerability of intranasal or intravenous administration of nalbuphine in infants. <i>Archives of disease in childhood</i> 108(1) 56–61. DOI:<a href=&quot;https://doi.org/10.1136/archdischild-2022-323807&quot;>10.1136/archdischild-2022-323807</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36100355/&quot;>https://pubmed.ncbi.nlm.nih.gov/36100355</a></p></li><li><p>Nie, X, et al., &amp; Wang, M (2023). Population pharmacokinetics of nalbuphine in patients undergoing general anesthesia surgery. <i>Frontiers in pharmacology</i> 14 1130287–None. DOI:<a href=&quot;https://doi.org/10.3389/fphar.2023.1130287&quot;>10.3389/fphar.2023.1130287</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37025491/&quot;>https://pubmed.ncbi.nlm.nih.gov/37025491</a></p></li><li><p>Lo, MW, et al., &amp; Whitney, CC (1987). The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. <i>European journal of clinical pharmacology</i> 33(3) 297–301. DOI:<a href=&quot;https://doi.org/10.1007/BF00637566&quot;>10.1007/BF00637566</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3691617/&quot;>https://pubmed.ncbi.nlm.nih.gov/3691617</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N02AF02;
